Compare Paychex, Inc. (PAYX) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Paychex, Inc. vs 10X Genomics Inc — how do they compare? Paychex, Inc. trades at $105.34 (market cap $37.19B), while 10X Genomics Inc trades at $84.56 (market cap $10.07B). The key difference: Paychex, Inc. is far larger — about 3.7× 10X Genomics Inc's market cap, and Paychex, Inc. pays a 4.56% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Paychex, Inc. for 56 Days and 10X Genomics Inc for 92 Days on average.
| PAYX | TXG | |
|---|---|---|
Market Cap | $37.19B | $10.07B |
Volume | 3,344,316 | 5,657,286 |
Sector | Industrials | Health |
52-Week High | $128.59 | $97.74 |
52-Week Low | $85.57 | $11.48 |
Typical Hold Time | 56 Days | 92 Days |
Enterprise Value | $40.87B | $9.59B |
Dividend Yield | 4.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Paychex (PAYX) trades at $101.55, up 0.52% on the day, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 27.35% net income margin and 47.06% ROE, but valuation ratios like P/E of 20.73 and P/S of 5.67 appear elevated. Recent news highlights mixed sentiment, with earnings outperformance offset by concerns over dividend sustainability and labor market cooling.
The outlook is cautious; while fundamentals remain solid with consistent revenue growth, high debt levels and bearish technicals pose risks. Analyst consensus leans hold with a $111 price target, suggesting limited upside. Key opportunities include dividend yield and PEO growth, but investors face headwinds from economic sensitivity and competitive pressures.
TXG trades at $76.10, down 5.65% on the day, reflecting a bearish technical trend. The company reported revenue of $642.82M for 2025 with a net loss of $43.54M, though it has consistently beaten quarterly EPS estimates. Recent news highlights strong demand for its Atera spatial biology platform and a patent victory. The stock faces resistance near $77 and support at $72.
The outlook is mixed; strong product demand and improving margins offer upside, but persistent losses and high valuation ratios pose risks. Analyst consensus is divided, with a $74.30 price target slightly below the current price, indicating cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Paychex, Inc.
Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
